Funding

List of centrally authorised products with safety-related changes to the product information

EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 October 2025, 09:30 (CEST) to 17 October 2025, 14:30 (CEST)

Report - EMA roundtable with stakeholders on the 20th anniversary of the SME regulation

PSUSA/00010473/202503

PSUSA/00010473/202503

Human medicines European public assessment report (EPAR): Fabhalta, iptacopan, Date of authorisation: 17/05/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Date of authorisation: 17/07/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Olumiant, baricitinib, Date of authorisation: 13/02/2017, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 15, Status: Authorised